Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-390-7 | CAS number: 68427-32-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The available study on decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7) is performed pre-GLP and before OECD guideline was available. It has been evaluated as Klimish rating 2 due to the limited reported study with basic data performed comparable to guideline/standard.
In the full scale test, rats were administered 1.0 to 6.4 ml/kg bodyweight of the tested product consisting of 45% decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7). Rats treated with water alone (6.4 ml/kg ) served as controls. Based on the identified specific density of the substance (CAS no 68427-32-7) of 1.44 g/ml as given under section 4.4 in IUCLID, the LD50 value will be between 2000 – 5000 mg/kg bw and thereforenot to be classified for acute toxicity according to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008.
During the observation period of 14 days, a record was kept of all mortalities and signs of toxicity. Signs of reaction to treatment, observed shortly after dosing, included lethargy and piloerection. These signs were accompanied by a slight increase in salivation in rats treated at 2.5 ml/kg and above and later by slight ataxia in female rats treated at 2.5 ml/kg and all rats at 4.0 and 6.4 ml/kg. Death occurred between two and ten hours after treatment. Autopsy revealed slight to moderate haemorrhage of the stomach and small intestines, and slight injection of mesenteric blood vessels. Slight darkening of the liver and kidneys was observed in four rats. Recovery of survivors, as judged by external appearance and behaviour, was apparently complete within 5 days of treatment. This observation was substantiated by normal bodyweight gains compared with controls, and normal autopsy findings. The acute median lethal oral dose (LD50) to rats of the tested product consisting of 45% a.s. was calculated to be: 5.7 mg/kg bodyweight. The corresponding LD50 value Decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7) is estimated to 2592 mg/kg bw based on concentration.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- October-November 1974
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Limited reported study with basic data given comparable to guideline/standard.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- Test was carried out before OECD guideline was available
- GLP compliance:
- no
- Remarks:
- pre-GLP
- Test type:
- standard acute method
- Species:
- rat
- Strain:
- other: CFY
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: no info
- Age at study initiation: no info
- Weight at study initiation: 95-120 g
- Fasting period before study: overnight
- Housing: no info
- Diet (e.g. ad libitum): no info
- Water (e.g. ad libitum): no info
- Acclimation period: no info
ENVIRONMENTAL CONDITIONS
- Temperature (°C): no info
- Humidity (%): no info
- Air changes (per hr): no info
- Photoperiod (hrs dark / hrs light): no info
IN-LIFE DATES: October-November 1974 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- VEHICLE: not used
MAXIMUM DOSE VOLUME APPLIED: 6.4 mL/kg bw
DOSAGE PREPARATION (if unusual): no info
- Doses:
- RF test: 0, 0.4, 1.6 and 6.4 mL/kg bw
Main test: 0, 1.0, 1.6, 2.5, 4.0 and 6.4 mL/kg bw - No. of animals per sex per dose:
- RF test: 2 (total of 16 rats)
Main study: 5 (total of 60 rats) - Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: no info
- Necropsy of survivors performed: yes - Statistics:
- LD50 and 95% confidence intervals were calculated by the method of Weil CS (1952) Biometrics, 8, 249
- Preliminary study:
- See below
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 - < 5 000 mg/kg bw
- Mortality:
- See data below
Death occurred between two and ten hours after treatment. - Clinical signs:
- other: Signs of reaction to treatment, observed shortly after dosing, includcd lethargy and piloerection. These signs were accompanied by a slight increase in salivation in rats treated at 2.5 ml/kg and above and later by slight ataxia in female rats treated at
- Gross pathology:
- Autopsy of deceased animals revealed slight to moderate haemorrhage of the stomach and small intestines, and slight injection of mesenteric blood vessels. Slight darkening of the liver and kidneys was observed in four rats. In survivors, autopsy findings were normal.
- Other findings:
- None
- Interpretation of results:
- Category 5 based on GHS criteria
- Remarks:
- Migrated information
- Conclusions:
- The LD50 value of 4.1 mL/kg in rats of the tested product consisting of 45% a.s. and the specific density of the substance decyldihydrogenphosphate, potassium salt (CAS no 68427-32-7) of 1.44 g/ml as given under section 4.4 in IUCLID, together with the stated concentration of 45%, the LD50 value of decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7) will be 2000 - 5000 mg a.i./kg bw.
- Executive summary:
Rats of the CFY strain were starved overnight before treatment with the tested product consisting of 45% decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7). The tested product consisting of 45% decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7) was administered undiluted, by oral intubation at a dosage volume in the full scale test of 1.0 to 6.4 ml/kg bodyweight. Rats treated with water alone (6.4 ml/kg ) served as controls.
During the observation period of 14 days, a record was kept of all mortalities and signs of toxicity. Signs of reaction to treatment, observed shortly after dosing, included lethargy and piloerection. These signs were accompanied by a slight increase in salivation in rats treated at 2.5 ml/kg and above and later by slight ataxia in female rats treated at 2.5 ml/kg and all rats at 4.0 and 6.4 ml/kg. Death occurred between two and ten hours after treatment. Autopsy revealed slight to moderate haemorrhage of the stomach and small intestines, and slight injection of mesenteric blood vessels. Slight darkening of the liver and kidneys was observed in four rats. Recovery of survivors, as judged by external appearance and behaviour, was apparently complete within 5 days of treatment. This observation was substantiated by normal bodyweight gains compared with controls, and normal autopsy findings. The acute median lethal oral dose (LD50) and its 95% confidence limits to rats of of the tested product consisting of 45% decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7) were calculated to be: 4.1 (3.1 to 5.5) ml/kg bodyweight.
Reference
RF test - mortality M / F
0 ml/kg: 0/2 & 0/2
0.4 ml/kg: 1/2 & 0/2 (25%)
1.6 ml/kg: 0/2 & 0/2
6.4 ml/kg: 2/2 & 2/2 (100%)
Main study: mortality M / F
0 ml/kg: 0/5 & 0/5
1.0 ml/kg: 0/5 & 0/5
1.6 ml/kg: 0/5 & 0/5
2.5 ml/kg: 1/5 & 1/5 (20%)
4.0 ml/kg: 3/5 & 2/5 (50%)
6.4 ml/kg: 3/5 & 5/5 (80%)
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 592 mg/kg bw
- Quality of whole database:
- The available data is considered to be of sufficient quality.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
The conclusion from the available study is that Decyldihydrogenphosphate, potassium salt (CAS: 68427 -32 -7) is not to be classified for acute toxicity according to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.